WebJun 19, 2024 · Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effective treatment for RVVC than other oral antifungal medicines. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment … WebFeb 15, 2024 · This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of acute VVC episodes in patients with RVVC and consists of 2 parts. The first part of the study is a 2-week induction phase for the treatment of the patient's …
Oteseconazole - Wikipedia
WebJan 6, 2024 · Oteseconazole non-inferior to fluconazole in the resolution of signs and symptoms at Day 14; Culture-verified recurrence from Day 14 through Week 50: Oteseconazole recurrence rate of 3.8%, fluconazole to placebo recurrence rate of 41.1% … WebJun 1, 2024 · DURHAM – Mycovia Pharmaceuticals has submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for oteseconazole, an oral antifungal product for the ... newnham faversham
Vivjoa: Uses, Dosage, Side Effects & Warnings - Drugs.com
WebJul 29, 2024 · Oteseconazole is the international nonproprietary name (INN). Oteseconazole is an azole antifungal used to prevent recurrent vulvovaginal candidiasis in females who are not of reproductive potential. Oteseconazole, also known as VT-1161, is a tetrazole antifungal agent potentially for the treatment of candidal vaginal infection. Weboteseconazole will increase the level or effect of dipyridamole by Other (see comment). Modify Therapy/Monitor Closely. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. Use lowest starting dose of BCRP substrate, or … newnham estate